Human medicines European public assessment report (EPAR): Enurev Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Adempas, riociguat, Date of authorisation: 27/03/2014, Revision: 17, Status: Authorised

Quality guidelines

Feedback from European Medicine Agency (EMA) to the EU Commission request to evaluate the feasibility of alternatives to replace titanium dioxide (TiO2) in medicinal products and its possible impact on medicines’ availability

Human medicines European public assessment report (EPAR): Tovanor Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Seebri Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 13, Status: Authorised

Clinical investigation of medicines for the treatment of Alzheimer's disease - Scientific guideline

Concept paper on the need for revision of the guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 11, Status: Authorised

Opinion on medicine for use outside EU: Pyramax, artesunate,pyronaridine, Malaria, 16/02/2012 Positive opinion